Vertex Pharmaceuticals | VRTX

Stock Price
440.75
Daily Change
-4.94 -1.11%
Monthly
10.34%
Yearly
29.64%
Q2 Forecast
433.25
Peers Price Chg Day Year Date
AbbVie 162.98 -1.51 -0.92% 12.48% May/21
Acadia Pharmaceuticals 15.27 0.17 1.13% -38.43% May/21
Agios Pharmaceuticals 33.88 0.69 2.08% 26.94% May/21
Alnylam Pharmaceuticals 149.62 -0.62 -0.41% -22.50% May/21
Amgen 314.85 0.42 0.13% 40.56% May/21
Arrowhead Research 25.02 0.20 0.81% -31.49% May/21
Biogen 227.44 -4.14 -1.79% -25.88% May/21
BioMarin Pharmaceutical 77.34 0.29 0.38% -16.63% May/21
Bristol-Myers Squibb 42.27 -1.02 -2.36% -35.77% May/21
Gilead Sciences 67.30 -0.55 -0.81% -14.40% May/21
Incyte 57.40 0.24 0.41% -10.86% May/21
Insmed 24.53 -1.01 -3.95% 20.78% May/21
Ionis Pharmaceuticals 37.37 -1.35 -3.49% -8.20% May/21
J&J 151.29 -0.18 -0.12% -3.56% May/21
Merck 130.76 -0.19 -0.15% 14.21% May/21
Moderna 143.69 2.79 1.98% 13.37% May/21
Neurocrine Biosciences 140.55 -1.10 -0.78% 50.32% May/21
Novartis 93.89 0.52 0.56% 2.90% May/21
Pfizer 28.53 0.10 0.35% -26.37% May/21
PTC Therapeutics 38.85 -1.27 -3.17% -34.26% May/21
Ultragenyx Pharmaceutical 40.58 -0.95 -2.29% -19.98% May/21
Regeneron Pharmaceuticals 994.45 8.17 0.83% 32.33% May/21
Roche Holding 234.40 -2.70 -1.14% -18.16% May/21
Sanofi 90.00 0.84 0.94% -10.27% May/21
Sarepta Therapeutics 129.12 -1.71 -1.31% -13.38% May/21
United Therapeutics 275.19 0.52 0.19% 25.89% May/21
Vertex Pharmaceuticals 440.75 -4.94 -1.11% 29.64% May/21

Indexes Price Day Year Date
US500 5326 13.28 0.25% 27.03% May/21
USND 16833 37.75 0.22% 32.32% May/21
US400 3015 -5.14 -0.17% 22.11% May/21
US100 18741 39.61 0.21% 35.32% May/21

Vertex Pharmaceuticals traded at $440.75 this Tuesday May 21st, decreasing $4.94 or 1.11 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals lost 10.34 percent. Over the last 12 months, its price rose by 29.64 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 433.25 by the end of this quarter and at 420.76 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.